<DOC>
	<DOCNO>NCT01875991</DOCNO>
	<brief_summary>The study estimate preference rheumatoid arthritis ( RA ) Plaque Psoriasis ( PsO ) patient self inject etanercept one two experimental autoinjector .</brief_summary>
	<brief_title>Preference Between Two Autoinjectors Patients With Rheumatoid Arthritis Plaque Psoriasis Treated With Etanercept</brief_title>
	<detailed_description>Candidates treatment determination investigator 's standard care care physician 's intent initiate treatment etanercept . Participants must naïve etanercept naïve autoinjector pen prefilled syrinx able self-inject . The study consist 30 day screen period , 2 treatment period 4 week duration ( one treatment period use Autoinjector A use Autoinjector B ) . At end study , participant may continue treatment commercially available etanercept physician 's discretion .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Diagnosis moderate severe Rheumatoid Arthritis ( RA ) moderate severe Plaque Psoriasis ( PsO ) candidate treatment etanercept opinion investigator addition care physician 's intent initiate treatment etanercept . Naive etanercept . Naive autoinjector pen prefilled syrinx Tumor Necrosis Factor ( TNF ) inhibitor therapy subcutaneous biologics RA . Willing selfinject per investigator judgement screen capable selfinjection use autoinjector A B document baseline investigator . Able read write English . Latex allergy . Subject active infection ( include chronic localized infection ) antiinfectives indicate within 4 week prior first dose etanercept . Subject prosthetic joint infection within 5 year screen native joint infection within 1 year screening . Other criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>